2002•PubMedRequires access

[Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist].

Takeshi Suzuki

Abstract

Anakinra, a recombinant human interleukin-1 receptor antagonist offers a new potent treatment for rheumatoid arthritis(RA). It is administered as a daily single subcutaneous injection. Recent randomized, double-blind, placebo-controlled trials revealed that anakinra significantly reduces the signs and symptoms of RA, reduces joint destruction, and is safe and tolerated. It was also revealed that anakinra is more potent when used in combination with methotrexate.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Anakinra, Interleukin 1 receptor antagonist, Medicine, Rheumatoid arthritis, Receptor antagonist, Antagonist, Placebo, Arthritis